Loading...
Loading...
KALV| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.3M |
| Gross Profit | -0.3M |
| Operating Expense | 31.7M |
| Operating I/L | -31.7M |
| Other Income/Expense | 5.4M |
| Interest Income | 0.8M |
| Pretax | -26.3M |
| Income Tax Expense | 13.7M |
| Net Income/Loss | -40.0M |
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company specializing in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio includes small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME), as well as oral plasma kallikrein inhibitors. Their products, such as KVD001 and sebetralstat, are designed to address these conditions, with some in advanced clinical trials. Additionally, the company is developing oral inhibitor programs targeting enzymes related to HAE. KalVista Pharmaceuticals generates revenue through the development and potential commercialization of these innovative pharmaceutical products.
